Literature DB >> 12660035

Unusual karyotype aberrations involving 2p12, 3q27, 18q21, 8q24, and 14q32 in a patient with non-Hodgkin lymphoma/acute lymphoblastic leukemia.

Roberta Okhowat1, Stefan Dorner, Wolfgang Hinterberger, Christa Fonatsch.   

Abstract

The t(2;18)(p12;q21), known as a rare variant of the t(14;18)(q32;q21), together with t(3;14)(q27;q32), t(8;15)(q24;q22) and two other unusual translocations involving chromosomes 6, 9, 12, and 13, were demonstrated in the bone marrow cells of a 70-year-old male with suspected non-Hodgkin lymphoma/acute lymphoblastic leukemia. The complex chromosomal aberrations were identified by chromosome banding analysis and by fluorescence in situ hybridization (FISH) with whole chromosome painting probes, centromere-specific alpha-satellite probes, and probes specific for genomic sequences of some likely to be involved candidate genes. Several but not all of the chromosomal aberrations could be proved by multicolor FISH. Possible mechanisms leading to this unusual karyotype commonly associated with different histologic lymphoma subtypes and their prognostic implications are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12660035     DOI: 10.1016/s0165-4608(02)00801-4

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  2 in total

1.  High levels of bcl-2 protein expression do not correlate with genetic abnormalities but predict worse prognosis in patients with lymphoblastic lymphoma.

Authors:  Yajun Gu; Yi Pan; Bin Meng; Bingxin Guan; Kai Fu; Baocun Sun; Fang Zheng
Journal:  Tumour Biol       Date:  2013-03-14

2.  Pleiotropy of cancer susceptibility variants on the risk of non-Hodgkin lymphoma: the PAGE consortium.

Authors:  Unhee Lim; Jonathan M Kocarnik; William S Bush; Tara C Matise; Christian Caberto; Sungshim Lani Park; Christopher S Carlson; Ewa Deelman; David Duggan; Megan Fesinmeyer; Christopher A Haiman; Brian E Henderson; Lucia A Hindorff; Laurence N Kolonel; Ulrike Peters; Daniel O Stram; Maarit Tiirikainen; Lynne R Wilkens; Chunyuan Wu; Charles Kooperberg; Loïc Le Marchand
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.